American CryoStem Corporation

American CryoStem Corporation (CRYO) is a clinical-stage biotechnology company, developing and delivering autologous (own self) regenerative therapies to treat diseases and conditions with significant unmet medical needs. We are prioritizing research targets and biological drug candidates where the disease biology is understood, and where our suite of technologies has the potential to make a difference. We are currently focused on mitigating the deleterious effects of post-concussion syndrome: https://clinicaltrials.gov/ct2/show/NCT04744051 and Long COVID/ PASC: Post Acute Sequelae of SARS-CoV-2 https://clinicaltrials.gov/ct2/show/NCT05669261 Translating Technology into Therapeutic TreatmentsTM Our core proprietary end-to-end patented technology platform consists of the Collection-Processing-Cryobanking and Delivery to Point-of-Care of Adipose...

Regenerative medicine,autologous mesenchymal stem cells ,tissue and cell based therapies,adipose tissue "atgraft" preparation and cryobanking,mesenchymal stromal cells "atcell" processing and cryobanking,end-to-end proprietary platform technology,autologous mscs for post-concussion syndrome ,autologous mscs for interventional treatment of long covid,pure adipose tissue for homologous wound healing treatments,master cell bank: single collection for a lifetime of treatments,atgraft treatments and therapies,atcell therapies,tissue harvesting system , transport delivery direct to point-of-care,"your cells. pure and simple.,and proprietary cell transport media

American cryostem corporation operates in the Biotechnology research industry.

American cryostem corporation's revenue is < 1m

American cryostem corporation has 11 - 50 employees.